144 related articles for article (PubMed ID: 30865387)
1. Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Walters EH
Drug Test Anal; 2019 Jul; 11(7):950-956. PubMed ID: 30865387
[TBL] [Abstract][Full Text] [Related]
2. Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Haydn Walters E
Drug Test Anal; 2017 Aug; 9(8):1262-1266. PubMed ID: 28033454
[TBL] [Abstract][Full Text] [Related]
3. Beta
Hostrup M; Narkowicz CK; Habib S; Nichols DS; Jacobson GA
Drug Test Anal; 2019 Jul; 11(7):1048-1056. PubMed ID: 30836453
[TBL] [Abstract][Full Text] [Related]
4. Beta2-Agonist Doping Control and Optical Isomer Challenges.
Jacobson GA; Fawcett JP
Sports Med; 2016 Dec; 46(12):1787-1795. PubMed ID: 27164986
[TBL] [Abstract][Full Text] [Related]
5. Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations.
Eibye K; Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Med Sci Sports Exerc; 2013 Jan; 45(1):16-22. PubMed ID: 22843108
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human.
Zhang M; Fawcett JP; Shaw JP
Br J Clin Pharmacol; 2002 Sep; 54(3):246-50. PubMed ID: 12236843
[TBL] [Abstract][Full Text] [Related]
7. Quantitative detection of inhaled formoterol in human urine and relevance to doping control analysis.
Deventer K; Pozo OJ; Delbeke FT; Van Eenoo P
Drug Test Anal; 2012 Jun; 4(6):449-54. PubMed ID: 22447497
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control.
Jessen S; Becker V; Rzeppa S; Backer V; Bengtsen KH; Hullstein I; Dehnes Y; Hostrup M
Drug Test Anal; 2021 Apr; 13(4):747-761. PubMed ID: 33210444
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the urinary threshold concentration of formoterol in sports drug testing.
Ventura R; Damasceno LM; Ramírez R; Farré M; Bergés R; Segura J
Drug Test Anal; 2013 Apr; 5(4):266-9. PubMed ID: 23355217
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective glucuronidation of formoterol by human liver microsomes.
Zhang M; Fawcett JP; Kennedy JM; Shaw JP
Br J Clin Pharmacol; 2000 Feb; 49(2):152-7. PubMed ID: 10671910
[TBL] [Abstract][Full Text] [Related]
12. The salmeterol anomaly and the need for a urine threshold.
Jacobson GA; Hostrup M
Drug Test Anal; 2022 Jun; 14(6):997-1003. PubMed ID: 32314556
[TBL] [Abstract][Full Text] [Related]
13. The influence of exercise and dehydration on the urine concentrations of salbutamol after inhaled administration of 1600 µg salbutamol as a single dose in relation to doping analysis.
Haase CB; Backer V; Kalsen A; Rzeppa S; Hemmersbach P; Hostrup M
Drug Test Anal; 2016 Jul; 8(7):613-20. PubMed ID: 26044066
[TBL] [Abstract][Full Text] [Related]
14. Assay validation for vilanterol and its metabolites in human urine with application for doping control analysis.
Panchal T; Baldwin S; Østergaard M; Hansen ESH; Backer V; Hostrup M; Daley-Yates P
Drug Test Anal; 2023 May; 15(5):495-505. PubMed ID: 36581315
[TBL] [Abstract][Full Text] [Related]
15. Beta
Onslev J; Jacobson G; Narkowicz C; Backer V; Kalsen A; Kreiberg M; Jessen S; Bangsbo J; Hostrup M
Eur J Appl Physiol; 2017 Sep; 117(9):1907-1915. PubMed ID: 28702809
[TBL] [Abstract][Full Text] [Related]
16. Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.
Pillard F; Lavit M; Cances VL; Rami J; Houin G; Didier A; Rivière D
Respir Res; 2015 Dec; 16():155. PubMed ID: 26704899
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a ultra high performance liquid chromatography-tandem mass spectrometric method for the direct detection of formoterol in human urine.
Sardela VF; Deventer K; Pereira HM; de Aquino Neto FR; Van Eenoo P
J Pharm Biomed Anal; 2012 Nov; 70():471-5. PubMed ID: 22841556
[TBL] [Abstract][Full Text] [Related]
18. Terbutaline: level the playing field for inhaled β
Jacobson GA; Hostrup M
Br J Sports Med; 2017 Sep; 51(18):1323-1324. PubMed ID: 27461883
[TBL] [Abstract][Full Text] [Related]
19. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
Van Holsbeke C; De Backer J; Vos W; Marshall J
Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
[TBL] [Abstract][Full Text] [Related]
20. Determination of salbutamol and salbutamol glucuronide in human urine by means of liquid chromatography-tandem mass spectrometry.
Mareck U; Guddat S; Schwenke A; Beuck S; Geyer H; Flenker U; Elers J; Backer V; Thevis M; Schänzer W
Drug Test Anal; 2011; 3(11-12):820-7. PubMed ID: 22081503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
